ICCM (ICCM) Stock Price & Analysis

ICCM (ICCM) fell 4.64% to USD 3.08 as of July 26, 2026 at 11:54 UTC, according to Nexqual real-time market data.

ICCM last closed at USD 3.23; the session ranged USD 3.01–3.3 on volume of 74,306 shares. Market capitalization is $10.55M, with a 52-week range of USD 2.12–42 (NCM). Source: Nexqual, July 26, 2026 at 11:54 UTC.

Key Statistics (as of July 26, 2026 at 11:54 UTC)

PriceUSD 3.08
Change▼ 4.64% (down)
Previous CloseUSD 3.23
OpenUSD 3.25
Day RangeUSD 3.01 – 3.3
52-Week RangeUSD 2.12 – 42
Volume74,306 shares
Market Cap$10.55M
ExchangeNCM

Technical Analysis (ICCM)

Nexqual's technical model rates ICCM "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 26, 2026 at 11:54 UTC.

Overall SignalSELL
RSI (14)41.79 (neutral)
vs SMA50Below (USD 4.95)
MACD-0.59 (negative)

Analyst Ratings (ICCM)

Wall Street analysts rate ICCM "None" based on 3 analysts, with a mean price target of USD 30.5 (range USD 30–31.5), per Nexqual as of July 26, 2026 at 11:54 UTC.

Consensus RatingNone
Analyst Count3
Mean TargetUSD 30.5
High TargetUSD 31.5
Low TargetUSD 30
Buy / Hold / Sell3 / 0 / 0

Earnings (ICCM)

Next Earnings Date2026-08-12
EPS EstimateUSD -1.38
Revenue Estimate$1.45M

Recent Earnings History

QuarterActual vs Estimate
2026-03-31USD -1.8 vs est -1.2 ▼ miss
2025-12-31USD -1.8 vs est -1.2 ▼ miss
2025-09-30USD -1.8 vs est -1.65 ▼ miss
2025-06-30USD -1.8 vs est -1.95 ▲ beat

Source: Nexqual, July 26, 2026 at 11:54 UTC.

Financials & Fundamentals (ICCM)

Total Revenue$3.56M
Revenue Growth (YoY)+25.70%
Gross Margin+36.55%
Operating Margin-466.19%
Profit Margin+0.00%
ROE-217.23%
Debt / Equity1.64
Current Ratio2.52
Total Cash$8.12M
Total Debt$139,000
Free Cash Flow$-8.88M

Source: Nexqual, July 26, 2026 at 11:54 UTC.

Financial Health Score (ICCM)

Nexqual rates ICCM's overall financial health "Weak" across five dimensions, as of July 26, 2026 at 11:54 UTC.

GrowthMixed — Revenue +2.7% YoY (annual), slow
ProfitabilityCritical — Heavily loss-making — early-stage company
Balance SheetStrong — $8M cash, no debt
Cash FlowWeak — FCF negative: -$9M, burning cash
EfficiencyCritical — ROE -217%, ROA -80.3%

Ownership (ICCM)

Insider Ownership+32.72%
Institutional Ownership+3.74%
Shares Outstanding3.43M
Float1.74M
Short % of Float+4.83%

Source: Nexqual, July 26, 2026 at 11:54 UTC.

Leadership (ICCM)

ICCM is led by Eyal Shamir (age 64), CEO & Director, per Nexqual as of July 26, 2026 at 11:54 UTC.

CEO & DirectorEyal Shamir (age 64)
Chief Operating OfficerShay Levav (age 47)
Vice President of Business Development & Global MarketingTlalit Bussi Tel-Tzure (age 54)
Vice President of Sales for North AmericaShad Good (age 47)
Chief Financial OfficerMeir Peleg (age 49)

Major Backers & Investors (ICCM)

Notable institutional backers of ICCM include Armistice Capital, LLC, Gunderson Capital Management LLC, UBS Group AG, according to Nexqual as of July 26, 2026 at 11:54 UTC.

Active Investors

InvestorStake
Armistice Capital, LLC2.64%
Gunderson Capital Management LLC0.58%
UBS Group AG0.15%

Source: Nexqual, July 26, 2026 at 11:54 UTC.

Peers & Related Stocks

SymbolNamePriceChange
SPRCSciSparc Ltd.USD 5.33▲ 10.12%
CDIOCardio Diagnostics Holdings IncUSD 1.55▼ 7.74%
HSCSHeartSciences Inc.USD 2.39▼ 4.4%
CMNDClearmind Medicine Inc.USD 1.61▼ 3.59%
QNRXQuoin Pharmaceuticals, Ltd.USD 4.28▼ 2.17%

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 11:54 UTC. This page is informational and not investment advice.